Quantcast
Last updated on April 18, 2014 at 15:29 EDT

Latest metronidazole Stories

2014-03-25 16:26:26

DUBLIN and LAVAL, Quebec, March 25, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals International in April 2013. Bacterial vaginosis...

2014-02-26 00:22:23

LAUSANNE, Switzerland, February 26, 2014 /PRNewswire/ -- - Galderma portfolio expands to offer a fast onset and long-acting alpha-2 adrenergic receptor agonist - Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso(R) (brimonidine) 3 mg/g gel. To view the Multimedia News Release, please...

2014-01-08 12:30:22

LAUSANNE, Switzerland, Jan. 8, 2014 /PRNewswire/ -- Galderma S.A. announced today that the Nomination and Compensation Committee of Galderma Pharma S.A. appointed industry veteran Stuart Raetzman to Chief Executive Officer of Galderma Laboratories, L.P. and Vice President North America, effective March 1, 2014. Raetzman was also elected to the company's Global Executive Committee. Raetzman will report directly to Humberto C. Antunes, President and CEO of Galderma S.A. Stuart Raetzman...

New Compounds Could Have Major Impact In Struggle Against Evolving Drug Resistance
2013-10-07 16:03:42

University of California - San Diego By tinkering with their chemical structures, researchers at the University of California, San Diego School of Medicine have essentially re-invented a class of popular antimicrobial drugs, restoring and in some cases, expanding or improving, their effectiveness against drug-resistant pathogens in animal models. Writing in the October 7 Early Edition of PNAS, Lars Eckmann, MD, professor of medicine, and colleagues describe creating more than 650 new...

2013-09-24 12:28:20

Study shows that new formulation with Ambophenol, Neurosensine and La Roche-Posay Thermal Spring Water has positive effect in management of rosacea-prone skin NEW YORK, Sept. 24, 2013 /PRNewswire/ -- A recent study, published in the August 2013 issue of the well-respected and peer-reviewed Journal of Drugs in Dermatology demonstrated that a formula containing three key ingredients known for their soothing and antioxidant properties - Ambophenol, Neurosensine and La Roche-Posay Thermal Spring...

2013-08-01 23:24:42

According to Dr. Joshua Fox, estimates for the total number of rosacea sufferers in the United States vary from 14 to 16 million. Many who suffer from the disease don’t understand rosacea symptoms and treatment options available for them. Roslyn, NY (PRWEB) August 01, 2013 Red splotches, facial flushing, unsightly bumps and pimples, bloodshot, watery eyes and even swelling of the nose are all symptoms which often fall under a general diagnosis of rosacea. But how is it possible to know...

2013-04-08 08:27:31

EXTON, Pa., April 8, 2013 /PRNewswire/ -- BioTrends Research Group and Arlington Medical Resources in their TreatmentTrends(®): Clostridium difficile Infections (EU) report find that the lack of hospital formulary inclusion, perceived high cost and reimbursement challenges, and lack of familiarity are the top three barriers to prescribing of Optimer/Cubist/Astellas' Dificlir (fidaxomicin) among surveyed physicians in the EU5. Fewer than 40 percent of represented hospitals in the EU5...

2013-03-11 08:28:01

Multi-Media Program Provides Epiduo(®) Gel Patients with Tools to Track Treatment FORT WORTH, Texas, March 11, 2013 /PRNewswire/ -- Galderma Laboratories, L.P. today announced the availability of the Epiduo(®) TAP (Treatment, Adherence, and Performance) Program, a first-of-its-kind online and mobile patient platform, powered by HealthPrize, that educates acne patients about the proper application of Epiduo(®) (adapalene and benzoyl peroxide 0.1%/2.5%) Gel and encourages acne...

2013-03-11 08:27:05

MISSISSAUGA, ON, March 11, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced the U.S. launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in...

2013-02-19 08:34:07

FORT WORTH, Texas, Feb. 19, 2013 /PRNewswire/ -- Galderma Laboratories, L.P. today announced that the U.S. Food and Drug Administration (FDA) has approved Epiduo(® )(adapalene 0.1%/BPO 2.5%) Gel to treat acne in children as young as 9 years old based on the results of a recent clinical study in pediatric patients. Epiduo(® )Gel had been previously approved for patients 12 years of age and older. "Pediatricians and dermatologists are seeing a steady increase in children reaching...